The present invention belongs to the field of pharmaceutical industry and relates to a pharmaceutical composition comprising an intragranulate phase and an extragranulate phase wherein the pharmaceutically active ingredient (API) 2 ({6 (3R) 3 aminopiperidin 1 yl 3 methyl 2 4 dioxo 3 4 dihydropyrimidin 1(2H) yl}methyl)benzonitrile or a pharmaceutically acceptable salt thereof is present in the intragranulate phase wherein said intragranulate phase is free from microcrystalline cellulose. Further the present invention relates to a process for preparing the same.